NOI to Sole Source to Central Admixture Services, Inc.
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH) Clinical Center intends to award a one-year, firm-fixed-price, sole-source contract to Central Admixture Pharmacy Services, Inc. (CAPS) for the provision of compounded sterile products, including Total Parenteral Nutrition (TPN) and renal replacement therapy. This is a Notice of Intent, not a request for quotation, and no solicitation will be issued. Comments regarding this sole-source determination are due by May 26, 2026, at 3 PM EST.
Purpose & Scope
The acquisition aims to secure select non-patient-specific sterile compounded products and patient-specific parenteral nutrition and renal replacement therapy for NIH Clinical Center patients. These products are critical for ongoing patient care and must meet stringent quality expectations. The requirement is for supplies/equipment, with an anticipated start date of June 2026.
Contract Details
- Type: Firm-Fixed-Price, Sole Source
- Duration: One year
- Anticipated Start: June 2026
- Authority: Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), and FAR 6.302-1 (Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements).
- Place of Performance: NIH Clinical Center, Bethesda, MD 20892, USA
- Product Service Code (PSC): 6515 – Medical And Surgical Instruments, Equipment, And Supplies
- NAICS Code: 325412 – Pharmaceutical Preparation Manufacturing
Justification for Sole Source
The NIH has determined that CAPS, Inc. is the original manufacturer and has not designated other distributors for the required compounded products in the U.S. These specialized services cannot be obtained through normal prime vendor distribution channels and can only be compounded by specific pharmacies in good standing with the FDA. Market research conducted by the NIH Clinical Center Pharmacy Department supports this singular distribution outlet. Contracts awarded under FAR Part 13 are exempt from FAR Part 6 competition requirements.
Response & Future Considerations
This is a Notice of Intent. The government's decision not to compete this requirement is solely within its discretion. Interested parties may submit comments referencing the posting number to Huda Malik, Contract Specialist, via email at huda.malik@nih.gov by May 26, 2026, at 3 PM EST. The NIH Clinical Center Pharmacy Department will continue to monitor the market for changes in distribution channels and may post a Sources Sought Notice if new competitive avenues emerge.